血液生物标志物与短期和长期轻度认知障碍发病风险
研究基于纵向观察性BIOCARD队列,在认知正常基线(基线1)和约7年后第二次基线(基线2)检测血浆Aβ42/Aβ40、p-tau181、NfL、GFAP、YKL40和sTREM2,用Cox回归分析其与轻度认知障碍(MCI)发病时间的关联。结果显示,在两个基线中,较低的Aβ42/Aβ40比值、较高的GFAP和较高的p-tau181/(Aβ42/Aβ40)比值均与MCI发病时间更早相关;基线2中较高的p-tau181和NfL也与7年内进展相关。校正AD生物标志物后,GFAP和NfL不再与MCI发病相关,YKL40和sTREM2则无关联。
要点
- 在认知正常人群中,较低的Aβ42/Aβ40比值、较高的GFAP和较高的p-tau181/(Aβ42/Aβ40)比值与MCI发病时间更早相关。
- 基线2中较高的p-tau181和NfL与7年内MCI发病相关,但校正AD生物标志物后GFAP和NfL不再显著。
- YKL40和sTREM2与MCI发病无关联。
核心结论
- 在临床前AD阶段,淀粉样蛋白(Aβ42/Aβ40)、p-tau181、神经变性(NfL)和神经炎症(GFAP)的血液标志物水平异常分别与从认知正常进展至MCI相关,但校正淀粉样蛋白和p-tau水平后,非AD特异性的神经变性和炎症标志物与症状发作无关。
研究设计与样本
- 纵向观察性BIOCARD研究,纳入认知未受损参与者,在基线1(271人,平均年龄57.5岁,60.5%女性,其中82人进展至MCI/痴呆)和基线2(202人,平均年龄64.5岁,62.4%女性,其中31人进展)采集血浆,使用NeuroToolKit(cobas Elecsys assays,Roche Diagnostics)检测生物标志物。
主要发现
- 基线1平均临床随访15.5年,基线2平均随访9.9年。
- 在两个基线中,较低的血浆Aβ42/Aβ40比值(HR均≤0.69,95%CI均≤0.55-0.87,p均≤0.034)、较高的GFAP(HR均≥1.83,95%CI均≥1.28-2.60,p均<0.002)和较高的p-tau181/(Aβ42/Aβ40)比值(HR均≥1.64,95%CI均≥1.25-2.13,p均≤0.001)均与MCI发病时间更早相关。
- 基线2中,较高的p-tau181(HR=2.07,95%CI=1.12-3.83,p=0.021)和较高的NfL(HR=1.75,95%CI=0.99-3.10,p=0.05)也与7年内MCI发病时间更早相关。
- 联合分析中,校正AD生物标志物水平(如p-tau181/(Aβ42/Aβ40))后,GFAP和NfL均与MCI发病无关,而AD生物标志物仍显著。
- YKL40和sTREM2与MCI发病无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ42/Aβ40 ratio), tau (p-tau181), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI. METHODS: Cognitively unimpaired participants from the longitudinal observational BIOCARD study provided blood plasma at their baseline evaluation ("baseline 1"). A second "baseline" specimen (collected using slightly different procedures) was evaluated for participants who were still cognitively normal approximately 7 years later. The plasma assays were based on the NeuroToolKit (cobas Elecsys assays, Roche Diagnostics). Cox regression models tested the association of biomarker levels with time to MCI symptom onset, separately for both baselines. RESULTS: Participants included 271 individuals at "baseline 1" (mean age = 57.5 years, 60.5% female, including 82 who progressed to MCI/dementia) and 202 individuals at "baseline 2" (mean age = 64.5 years, 62.4% female, including 31 progressors). The mean clinical follow-up was 15.5 years for "baseline 1" and 9.9 years for "baseline 2." For both baselines, lower plasma Aβ42/Aβ40 ratio (both hazard ratios, HRs ≤ 0.69, 95% CIs ≤ 0.55-0.87, p ≤ 0.034), higher GFAP (HRs ≥ 1.83, CIs ≥ 1.28-2.60, p < 0.002), and a higher ratio of p-tau181/(Aβ42/Aβ40) (HRs ≥ 1.64, CIs ≥ 1.25-2.13, p ≤ 0.001) were each associated with an earlier time to MCI symptom onset. For baseline 2, higher p-tau181 (HR = 2.07, CI = 1.12-3.83, p = 0.021) and higher NfL (HR = 1.75, CI = 0.99-3.10, p = 0.05) were also associated with earlier MCI symptom onset for progression within 7 years. When combining biomarkers, neither GFAP nor NFL was associated with MCI symptom onset after accounting for AD biomarker levels (e.g., p-tau181/(Aβ42/Aβ40)), which remained significant. YKL40 and sTREM2 were not associated with MCI onset. DISCUSSION: Results indicate that during preclinical AD, more abnormal blood biomarker levels of amyloid (Aβ42/Aβ40), p-tau181, neurodegeneration (NfL), and neuroinflammation (GFAP) individually are associated with progression from normal cognition to MCI, but the AD-nonspecific neurodegeneration and inflammation markers were not associated with symptom onset after accounting for amyloid and p-tau levels.
引用
- Soldan A, Pettigrew C, Wang J, et al. Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term. Neurology. 2024. PMID: 39724536. doi:10.1212/WNL.0000000000210225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。